Phase Ib/II trial of envafolimab, a novel subcutaneous singledomain anti-PD-L1 monoclonal antibody, plus lenvatinib in patients with selected advanced solid tumors

被引：0
|
作者：
Liu, T. [1 ]
Feng, Y. [1 ]
Xu, X. [1 ]
Ren, X. [2 ]
Jia, J. [3 ]
Pan, H. [4 ]
Wang, B. [5 ]
Wu, B. [6 ]
Cao, X. [7 ]
Liu, J. [8 ]
Yang, Y. [9 ]
Xiao, S. [10 ]
Qin, L. [10 ]
Zhu, D. [10 ]
Xu, S. [10 ]
Huang, W. [10 ]
机构：
[1] Fudan Univ, Zhongshan Hosp, Dept Oncol, Shanghai, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Dept Biol Therapy, Tianjin, Peoples R China
[3] Dongguan Peoples Hosp, Dept Oncol, Dongguan, Peoples R China
[4] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Sch Med, Hangzhou, Peoples R China
[5] 960th Hosp PLA Joint Logist Support Force, Dept Oncol, Jinan, Peoples R China
[6] China Med Univ, Shengjing Hosp, Dept Urol, Shenyang, Peoples R China
[7] Shanxi Med Univ, Hosp 1, Dept Urol, Taiyuan, Peoples R China
[8] Dalian Med Univ, Affiliated Hosp 1, Dept Med Oncol, Dalian, Peoples R China
[9] Kunming Med Univ, Yunnan Canc Hosp, Affiliated Hosp 3, Dept Urol, Kunming, Peoples R China
[10] 3D Med Inc, Dept Clin Dev, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2188
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1049P
引用
收藏
页码：S635 / S635
页数：1
相关论文
共 50 条
  • [41] Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma
    Tang, Bixia
    Xiao, Jun
    Chi, Zhihong
    Duan, Rong
    Cui, Chuanliang
    Si, Lu
    Liu, Yixun
    Hu, Xuechun
    Liu, Zhi
    Xiang, Ping
    Li, Siming
    Yan, Xieqiao
    Zhou, Li
    Li, Juan
    Li, Yujie
    Yu, Xiaohui
    Dai, Xiangrong
    Li, Xiaoyi
    Guo, Jun
    Sheng, Xinan
    ONCOLOGIST, 2024,
  • [42] Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors
    Subbiah, Vivek
    Grilley-Olson, Juneko E.
    Combest, Austin J.
    Sharma, Neelesh
    Tran, Richard H.
    Bobe, Lulian
    Osada, Atsushi
    Takahashi, Kazuhiro
    Balkissoon, Jaikrishna
    Camp, Aaron
    Masada, Atsuhiro
    Reitsma, Dirk J.
    Bazhenova, Lyudmila A.
    CLINICAL CANCER RESEARCH, 2018, 24 (01) : 43 - 51
  • [43] Envafolimab - first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors
    Chen, Mifen
    Jiang, Mengyun
    Wang, Xinhui
    Shen, Lin
    Li, Jian
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (10) : 1227 - 1232
  • [44] A PHASE IB TRIAL OF ZIV-AFLIBERCEPT PLUS PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Tyan, Kevin
    Rahma, Osama
    Giobbie-Hurder, Anita
    Brohl, Andrew
    Bedard, Philippe
    Renouf, Daniel
    Sharon, Elad
    Streicher, Howard
    Hathaway, Emma
    Cunningham, Rachel
    Manos, Michael
    Severgnini, Mariano
    Rodig, Scott
    Hodi, F. Stephen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A402 - A404
  • [45] Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors.
    Shimizu, Toshio
    Nakajima, Takako Eguchi
    Lu, Ni
    Xue, Shilin
    Xu, Wenlian
    Fu, Meng
    Cao, Walt
    Lu, Haolan
    Liu, David
    Dong, RuiPing
    Wang, Xiaoxiao
    Wang, Pilin
    Zhu, Danming
    Xu, Ting
    Gong, John
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] Avelumab (MSB0010718C; anti-PD-L1), in Japanese patients with advanced gastric cancer: results from phase Ib trial
    Hironaka, Shuichi
    Shitara, Kohei
    Iwasa, Satoru
    Nishina, Tomohiro
    Muro, Kei
    Esaki, Taito
    Satoh, Taroh
    Hara, Hiroki
    Machida, Nozomu
    von Heydebreck, Anja
    Shimizu, Akiko
    Doi, Toshihiko
    ANNALS OF ONCOLOGY, 2016, 27
  • [47] Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
    Patnaik, Amita
    Kang, S. Peter
    Rasco, Drew
    Papadopoulos, Kyriakos P.
    Elassaiss-Schaap, Jeroen
    Beeram, Muralidhar
    Drengler, Ronald
    Chen, Cong
    Smith, Lon
    Espino, Guillermo
    Gergich, Kevin
    Delgado, Liliana
    Daud, Adil
    Lindia, Jill A.
    Li, Xiaoyun Nicole
    Pierce, Robert H.
    Yearley, Jennifer H.
    Wu, Dianna
    Laterza, Omar
    Lehnert, Manfred
    Iannone, Robert
    Tolcher, Anthony W.
    CLINICAL CANCER RESEARCH, 2015, 21 (19) : 4286 - 4293
  • [48] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    Toshio Shimizu
    Takashi Seto
    Fumihiko Hirai
    Mitsuhiro Takenoyama
    Kaname Nosaki
    Junji Tsurutani
    Hiroyasu Kaneda
    Tsutomu Iwasa
    Hisato Kawakami
    Kazuo Noguchi
    Takashi Shimamoto
    Kazuhiko Nakagawa
    Investigational New Drugs, 2016, 34 : 347 - 354
  • [49] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    Shimizu, Toshio
    Seto, Takashi
    Hirai, Fumihiko
    Takenoyama, Mitsuhiro
    Nosaki, Kaname
    Tsurutani, Junji
    Kaneda, Hiroyasu
    Iwasa, Tsutomu
    Kawakami, Hisato
    Noguchi, Kazuo
    Shimamoto, Takashi
    Nakagawa, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (03) : 347 - 354
  • [50] JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti-PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.
    Hyman, David Michael
    Zelnak, Amelia B.
    Bauer, Todd Michael
    Ulahannan, Susanna Varkey
    Ford, James M.
    Cesari, Rossano
    Hoyle, Margaret
    Chappey, Colombe
    Stewart, Ross
    Conte, Umberto
    Yap, Timothy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345